Ohio's Proposed Ban On Sales Marks Kratom Industry's Latest Battlefront
This article was originally published in The Rose Sheet
Ohio Board of Pharmacy proposes placing into Schedule I kratom constituent ingredients mitragynine and 7-hydroxymitragynine, a change that would prohibit kratom sales in the state. The board's findings "parrot the false propaganda" of FDA in its "crusade to ban kratom," says the American Kratom Association.
You may also be interested in...
NPA wants to work with FDA to develop broader, more transparent medical food definition; FTC FY 2018 report notes enforcements against supplement firms making false claims of memory and cognitive benefits; Zero Xtreme recalled for second time in two years after found containing sibutramine; and more news.
"Based on the scientific information in the literature and further supported by our computational modeling and the reports of its adverse effects in humans, we feel confident in calling compounds found in kratom, opioids," says Commissioner Scott Gottlieb.